Sterious Steve, Smaldone Marc C, Plimack Elizabeth, Uzzo Robert G, Canter Daniel, Kutikov Alexander
Department of Surgucal Oncology, Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Can J Urol. 2012 Dec;19(6):6578-80.
Surgical excision is the gold standard therapy for clinically localized renal masses. Nevertheless, prognostication of the natural history of untreated renal cell carcinoma (RCC) remains a clinical challenge. While active surveillance (AS) has emerged as a viable treatment option in select patients with localized tumors and significant competing mortality risks, long term follow up data to assess the risk of disease progression are limited. We present a case of a localized, clinical stage T2 renal mass progressing to regional and systemic disease over 6 years, demonstrating that kinetics of disease progression may be prolonged and are yet to be fully understood.
手术切除是临床局限性肾肿块的金标准治疗方法。然而，对未经治疗的肾细胞癌（RCC）自然病史进行预后评估仍然是一项临床挑战。虽然主动监测（AS）已成为部分患有局限性肿瘤且存在重大竞争性死亡风险患者的一种可行治疗选择，但用于评估疾病进展风险的长期随访数据有限。我们报告一例局限性临床分期为T2期的肾肿块在6年内进展为局部和全身疾病的病例，表明疾病进展的动力学可能会延长，且尚未完全被理解。
